Roche CEO: our obesity market hopes have remained intact for 2 yrsFRANKFURT, Jan 29 (Reuters) - Roche's CEO said on Thursday that the Swiss drugmaker's expectations about opportunities in the future obesity drug market have not diminished since its Carmot Therapeutics takeover deal in late 2023.
(Reporting by Ludwig Burger, Editing by Friederike Heine)
((ludwig.burger@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments